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Abstract
Aims Type 2 diabetes mellitus is a major cause of death and disability due to its long-term macro- and microvascular diseases. 
Although women with type 2 diabetes have more macrovascular diseases, it is unclear whether there are sex differences in 
the occurrence of microvascular disease. The aim of our study was to investigate sex differences in the incidence of micro-
vascular complications in type 2 diabetes.
Methods Analyses were performed in the DiaGene study, a prospective cohort study for complications of type 2 diabetes, 
collected in the city of Eindhoven, the Netherlands (n = 1886, mean follow-up time = 6.93 years). Cox proportional hazard 
models adjusted for risk factors for complications (age, smoking, hypertension, dyslipidemia, HbA1c and duration of type 
2 diabetes) were used to analyze the incidence of microvascular complications in men and women.
Results The incidence of microalbuminuria was significantly higher in men (HR microalbuminuria 1.64 [CI 1.21–2.24], 
p = 0.002). Additionally, men are more likely to develop two or three microvascular complications compared to women (OR 
2.42 [CI 1.69–3.45], p < 0.001).
Conclusions This study shows that men with type 2 diabetes are more likely to develop microvascular complications, espe-
cially microalbuminuria. Furthermore, men seem to have a higher chance of developing multiple microvascular complica-
tions. Our results highlight that men and women may not benefit to a similar extent from current treatment approaches to 
prevent diabetes-related microvascular diseases.
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Introduction
Type 2 diabetes mellitus is a large and growing healthcare 
problem that leads to macro- and microvascular complica-
tions [1]. Type 2 diabetes is a health threat to both men and 
women. Nonetheless, sex differences have been described 
in the occurrence of macrovascular complications, where 
women with type 2 diabetes are more often and worse 
affected than men [2]. So far, these differences have not 
resulted in sex-specific recommendations in the guidelines 
[3, 4]. It is uncertain whether sex differences exist in the 
prevalence and incidence of microvascular diseases in type 2 
diabetes. Insights into differences between men and women 
may fuel development of more personalized treatment 
approaches. Existing studies show ambiguous outcomes, 
and not all microvascular outcomes have been investigated 
to the same extent. In a study by Stratton et al. [5], 6 years 
after diagnosis of type 2 diabetes, men had more diabetic 
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retinopathy than women. In contrast, in a cross-sectional 
study of Korean patients, no sex difference was observed in 
prevalence rate of retinopathy [6]. Similar level of dispar-
ity has been reported on sex differences for neuropathy [7, 
8] and albuminuria, reflecting microvascular renal disease 
[9–11]. Taken together, there is a lack of large prospective 
follow-up studies systematically investigating sex differ-
ences for each microvascular complication and the total 
burden of microvascular complications. We determined the 
sex difference in the incidence of each of the microvascular 
complications in the DiaGene study. In addition, we ana-




The design of the DiaGene study has been described previ-
ously [12]. In short, the DiaGene study is an all lines of care 
case–control study in Eindhoven and Veldhoven that was 
coordinated by the vascular section of the internal medicine 
department in the Erasmus MC. Virtually all type 2 diabe-
tes patients in Eindhoven and Veldhoven were approached. 
Eventually 1886 patients with type 2 diabetes were included. 
Written informed consent was obtained from all participants. 
This study was approved by the Medical Ethics Committees 
of the Erasmus MC, Catharina Hospital and Maxima Medi-
cal Center.
Definitions microvascular complications
Type 2 diabetes was defined in accordance with American 
Diabetes Association and World Health Organization guide-
lines, as described previously [13, 14]. Diabetic retinopathy 
was scored according to the report of an ophthalmologist 
as absent or present. If present, it was classified as non-
proliferative, proliferative or retinopathy treated with pho-
tocoagulation or intra-vitreal injections. Neuropathy was 
diagnosed by a podotherapist, neurologist or the treating 
physician. Microalbuminuria as a reflection of microvascu-
lar renal disease was defined as (albumin creatinine ratio 
(ACR) ≥ 2.5 for men or ≥ 3.5 for women) at two of three 
consecutive measurements, or when high microalbuminu-
ria or macroalbuminuria was present at one measurement 
(ACR ≥ 12.5 for men and ≥ 17.5 for women) [12].
Clinical data
Laboratory data and anthropometrics were derived from 
medical records at inclusion. By means of a questionnaire, 
medical history, family history and lifestyle information 
was collected. Systolic blood pressure (SBP) > 140 mmHG 
and/or diastolic blood pressure (DBP) > 90 mmHg or use 
of antihypertensive therapy defined hypertension. Mean 
arterial pressure (MAP) was calculated with the formula 
(2 × diastolic pressure + systolic pressure)/3. Dyslipidemia 
was defined as LDL > 3.0 or usage of lipid-lowering medica-
tion. Non-HDL cholesterol was calculated with the formula 
non-HDL = total cholesterol-HDL cholesterol. Smoking sta-
tus was defined as current smoker, former smoker or never 
smoker.
Endpoints
Primary endpoints were each of the above-described micro-
vascular complications: retinopathy, microalbuminuria and 
neuropathy. These microvascular complications were defined 
as absent or present. Neuropathy data were only available for 
outpatient hospital clinic patients. Analyses on neuropathy 
and the total burden of microvascular complications were 
therefore restricted to the hospital population (n = 830).
Statistical analysis
To compare baseline variables, the independent samples T 
test was applied for continuous variables with a normal dis-
tribution and the Chi-square test for categorical variables. In 
cross-sectional analyses, applying multiple logistic regres-
sion models, odds ratio (ORs) and 95% confidence intervals 
(CIs) were estimated for the association between sex and 
prevalent microvascular complications. In the prospective 
analyses, using Cox proportional hazard models, hazard 
ratios (HRs) and 95% CIs were estimated to study the asso-
ciation between sex and first incident microvascular compli-
cation. All analyses were adjusted for potential confounders: 
age, smoking, MAP, dyslipidemia (non-HDL cholesterol and 
HDL cholesterol), HbA1c and duration of type 2 diabetes. 
In the prospective analyses, prevalent cases of the studied 
complication at baseline were excluded. To explore possible 
premenopausal hormonal effects, all analyses were repeated 
excluding women under the age of 51 years [15]. To inves-
tigate a possible interaction between sex and smoking, this 
interaction term was added as covariate in the models. To 
study the relationship of sex with the occurrence of multiple 
simultaneous complications at baseline and follow-up, ordi-
nal logistic regression was performed. The dependent vari-
able, number of microvascular complications was ordered 
in three categories, zero and one microvascular complica-
tions were classified as the reference category and two or 
three microvascular complications were the other separate 
categories. Additional models were corrected for risk fac-
tors for microvascular complications: age, smoking, MAP, 
dyslipidemia (non-HDL cholesterol and HDL cholesterol), 
HbA1c and duration of type 2 diabetes. Venn diagrams were 
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created using R version 3.6.1 with package “Eulerr.” p < 0.05 
was considered statistically significant. Statistical analyses 
were performed using SPSS version 22.0.
Results
Baseline patient characteristics
Baseline characteristics for men and women are shown in 
Table 1. Two patients were excluded because of unknown 
sex, leaving a total of 1884 patients for analyses. Women 
had a significantly longer time of follow-up (7.05 years 
vs. 6.83  years, p = 0.03), higher BMI (31.43  kg/cm2 
Table 1  Baseline characteristics 
of men and women in the 
DiaGene study
Unless stated otherwise, mean (± SD) are given
DiaGene Men (n = 1006) Women (n = 878) p Value
Age (years) 64.74 (± 10.44) 65.82 (± 10.69) 0.026
Duration of diabetes (years) 9.84 (± 8.14) 10.38 (± 8.78) 0.179
Mean follow-up (years) 6.83 (± 2.19) 7.05 (± 2.05) 0.030
BMI (kg/m2) 29.63 (± 4.63) 31.43 (± 6.09)  < 0.001
MAP (mmHg) 99.25 (± 10.87) 98.47(± 10.75) 0.133
HbA1c (%) 7.02 (± 1.08) 7.07 (1.05) 0.326
HbA1c (mmol/mol) 53 (± 12) 53 (± 11) 0.326
Total cholesterol (mmol/L) 4.14 (± 0.88) 4.47 (± 0.95)  < 0.001
LDL cholesterol (mmol/L) 2.35 (± 0.79) 2.55 (± 0.85)  < 0.001
HDL cholesterol (mmol/L) 1.09 (± 0.30) 1.26 (± 0.32)  < 0.001
Non-HDL cholesterol (mmol/L) 3.04 (± 0.860) 3.21 (± 0.94)  < 0.001
Primary care (%) 562 (56) 494 (56) 0.862
Secondary care (%) 444(44) 384(44)
Dyslipidemia (%) 563 (56) 530 (60) 0.100
Missing data (%) 91 (9) 67 (8)
Smoking (%)  < 0.001
 Never smoked 131 (13) 309 (35)
 Current smoker 190 (19) 115 (13)
 Former smoker 607 (60) 305 (40)
 Missing data (%) 78 (8) 104 (12)
Diabetes medication (%)
 No 177 (18) 163 (19) 0.508
 Insulin and analogues 297 (29) 275 (31) 0.309
 Oral antidiabetics 616 (61) 524 (60) 0.653
 Missing data (%) 55 (5) 57 (6)
Use of antihypertensive medication (%) 662 (66) 591 (67) 0.295
Missing data (%) 55 (5) 57 (6)
Use of lipid-lowering medication agents (%) 670 (66) 563 (64) 0.392
Missing data (%) 55 (5) 57 (6)
Macrovascular complications (%) 415 (41) 245 (28)  < 0.001
 Ischemic heart disease (%) 329 (33) 168 (20)  < 0.001
 Ischemic brain disease (%) 128 (13) 83 (10) 0.019
 Missing data (%) 57 (6) 76 (9)
Microvascular complications (%) 402 (40) 262 (31)  < 0.001
 Retinopathy (%) 184 (18) 124 (15) 0.032
 Microalbuminuria (%) 263 (26) 124 (15)  < 0.001
 Neuropathy (%) 126 (12) 112 (13) 0.727
 Missing data (%) 138 (13) 146 (17)
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vs. 29.63  kg/cm2, p < 0.001), higher HDL cholesterol 
(1.26 mmol/L vs. 1.09 mmol/L, p < 0.001), higher non-HDL 
cholesterol (3.21 mmol/L vs. 3.04 mmol/L, p < 0.001) and 
were older (65.82 years vs. 64.74 years, p = 0.026) compared 
to men. In contrast, men were significant more likely to be 
current (19% vs. 13%, p < 0.001) and former smokers (60% 
vs. 13%, p < 0.001) than women.
Sex and prevalent complications at baseline
In cross-sectional analyses at baseline, men had more 
macro- and microvascular complications. Men had signifi-
cantly higher age adjusted odds ratio for retinopathy [OR 
1.36 (CI 1.06–1.75)] and microalbuminuria [OR 2.38 (CI 
1.87–3.04)]. These associations remain significant for both 
retinopathy [OR 1.98 (CI 1.39–2.81)] and microalbuminuria 
[OR for men 1.85 (CI 1.37–2.49)] after adjustment for mul-
tiple confounders (Supplementary Table 1). No significant 
differences between the sexes were found for neuropathy 
at baseline. There was no significant interaction between 
smoking and sex for all microvascular complications. Also 
excluding women under the age of 51 years from the analy-
ses did not substantially change these results (Supplemen-
tary Table 2).
Sex and incident complications at follow‑up
Table 2 shows the Cox proportion hazard models for pro-
spective analyses. No significant differences were found in 
retinopathy and neuropathy. Men had a significant higher 
hazard ratio for microalbuminuria [HR 1.64 (CI 1.21–2.24)] 
in both models. There was no significant interaction between 
smoking and sex on the outcomes of retinopathy and neu-
ropathy. For microalbuminuria, a significant association of 
this interaction term was seen in both models [HR 0.60 (CI 
0.38–0.96)], indicating a more detrimental effect of smok-
ing in women. Excluding women under the age of 51 years 
from the analyses did not substantially change these results 
(Supplementary Table 3).
Total burden of complications in men and women 
at baseline and follow‑up
At baseline and follow-up, men were significantly more 
likely than women to have two or three microvascular com-
plications also after correction for conventional risk factors 
(Table 3) (OR 2.42 [CI 1.69–3.45] at follow-up for the fully 
adjusted model). Figure 1 illustrates the overlap of complica-
tions in men and women at baseline and follow-up, only for 
the secondary care patients.
Table 2  Hazard ratios for 
incident microvascular 
complications according to sex
Women are the reference group
Model 0: adjusted for age
Model 1: additionally adjusted for smoking, HbA1c, MAP, non-HDL cholesterol, HDL cholesterol and 
duration of diabetes * Adding covariates interaction term sex * smoking, line of care and BMI did not 
change results significantly
HR hazard ratio, CI confidence interval
Model 0 HR 95% CI p Value Model 1 HR 95% CI p Value
Retinopathy
Men
1.13 0.87–1.47 0.360 1.27 0.93–1.74 0.130
Microalbuminuria
Men
1.89 1.46–2.44  < 0.001 1.64 1.21–2.24 0.002
Neuropathy
Men
1.28 0.99–1.65 0.061 1.35 0.99–1.83 0.057
Table 3  Ordinal regression of 
microvascular complications at 
baseline and follow-up
Women are the reference group
Model 0: adjusted for age
Model 1: additionally adjusted for smoking, HbA1c, MAP, non-HDL cholesterol, HDL cholesterol and 
duration of diabetes
OR odds ratio, CI confidence interval
Baseline OR 95% CI p Value Follow-up OR 95% CI p Value
Model 0
Men
1.73 1.23–2.43 0.002 2.45 1.83–3.29  < 0.001
Model 1
Men




In our large prospective cohort study of patients with type 2 
diabetes, we found sex differences in microvascular compli-
cations at baseline and at prospective follow-up, with men 
being more affected than women. At baseline, men had a 
significantly higher frequency of microalbuminuria and retin-
opathy. Prospective analyses showed that men are more at 
risk of developing microalbuminuria. In addition, men were 
more likely to develop multiple microvascular complications, 
while women more often had one isolated complication.
In contrast to macrovascular disease, little is known about 
sex differences in microvascular complications in type 2 
diabetes due to paucity of prospective data. Therefore, we 
decided to perform this prospective study, with ample infor-
mation on all microvascular complications and confounding 
factors. The results of our study are partly in line with pre-
vious retrospective, cross-sectional and prospective studies 
on sex difference in microvascular complications. Regard-
ing retinopathy, a cross-sectional study by Looker et al. [16] 
found that retinopathy was associated with male sex after 
correcting for risk factors. Also prospective analyses by 
Semeraro et al. [17] and Stratton et al. [5] showed significant 
positive associations of retinopathy with male sex. Interest-
ingly, Ozawa et al. [18] found the relationship between dia-
betic retinopathy and men appears to weaken with longer 
duration of type 2 diabetes. We did not find significant dif-
ferences in the incidence of retinopathy between men and 
women, although retinopathy was more prevalent in men at 
baseline. For albuminuria, previous cross-sectional studies 
reported a higher prevalence in men [19, 20]. Prospective 
studies have shown conflicting results reporting positive [9], 
negative [21] and absent [22] associations of male sex with 
albuminuria. Regarding neuropathy, in Caucasians a higher 
prevalence in men was found [7]. In contrast, in Asians, a 
higher prevalence of neuropathy among women was reported 
[8]. Of note, these studies did not correct for height, which 
was shown to be more strongly associated with neuropathy 
than sex [23]. We could unfortunately also not correct for 
height, as we did not have this available as an independent 
measurement. Part of the higher prevalence in retinopathy 
and incidence and prevalence in microalbuminuria in men 
may be explained by differences in risk factors for these com-
plications between men and women. In our study, men were 
Fig. 1  Overlap microvascular complications at baseline and follow-up in outpatient clinic patients according to sex
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more often current and former smokers. In contrast, women 
had higher total, LDL and non-HDL cholesterol levels. These 
findings are in line with other studies [24, 25]. However, after 
correction for these risk factors, the sex effect on microvas-
cular disease remained. Additional analyses, and also adjust-
ing for other risk factors such as BMI and line of care in 
the models did not change the results substantially (data not 
shown). Because men were more often current and former 
smoker, we investigated a potential interaction of smoking 
and sex. This interaction was nonsignificant for the major-
ity of outcomes. In microalbuminuria, it showed that smok-
ing in women is associated with a higher risk. This effect 
therefore does not explain the higher risk of nephropathy in 
men. It therefore seems unlikely that smoking explains these 
differences, but we cannot exclude a residual undetectable 
level of microvascular damage due to differences in smok-
ing habits and smoking history between men and women 
at baseline. As men and women were represented in equal 
proportions in primary and secondary care and the guide-
lines for treatment in these lines of care were identical, this 
also does not seem to play a role in the findings, unlike what 
was observed elsewhere [26]. Taken together, these findings 
suggest that residual uncorrected differences or yet unknown 
factors may play a role. One of these may be the difference 
in sex hormones. For macrovascular complications, it is 
known that men and postmenopausal women have a higher 
risk of cardiovascular disease compared to premenopausal 
women, which suggests a protective effect of endogenous 
female hormones such as estrogen and progesterone [27]. 
Several studies have reported that lower testosterone levels 
in men with type 2 diabetes are associated with macrovascu-
lar complications and that higher testosterone levels in men 
are associated with lower cardiovascular disease (CVD) and 
all-cause mortality [28, 29]. However, the association of sex 
hormones with microvascular complications is unknown. To 
investigate a possible hormonal explanation, we repeated our 
analyses excluding women younger than 51 years of age. We 
observed no substantial changes in the results. These analy-
ses take sex hormones differences as the definite explanation 
unlikely. However, it cannot be ruled out that the difference in 
premenopausal exposure to sex hormones between men and 
women may partly account for our findings.
Not only sex differences but also gender differences 
in behavior and treatment between men and women may 
be involved in the differences in outcomes. A study of 
Kramer et al. [30] observed that men are treated more 
intensively for type 2 diabetes and CVD, which may 
result in earlier diagnosis and treatment of complications. 
Another study observed less effective treatment of lipid 
disorders in women [31]. These differences would, how-
ever, be expected to result in a lower rather than higher 
microvascular complication rate in men. Moreover, the 
participants in our study were all treated according to the 
current guidelines for type 2 diabetes and prevention of 
complications. We have no indications from our data that 
women were treated less stringent. They were treated with 
lipid-lowering therapy, antidiabetic medication and anti-
hypertensive medication in equal rates. We cannot exclude 
differences in medications adherence between men and 
women. There are several studies that conclude that women 
have a lower medication adherence compared to men [32]. 
This may be a possible explanation of the significant dif-
ferences in lipid status of men and women in our study, but 
does not explain a higher microvascular complication rate 
in men. Strengths of our study are the prospective study 
design, large study size and meticulous collection of phe-
notypic, medication and risk factor data. Although we have 
performed our study with great care, we need to consider 
some limitations. First, stages of diabetic nephropathy are 
defined based on magnitude of albuminuria and kidney 
function estimated by eGFR. Diabetic nephropathy can 
follow a non-albuminuric pathway to renal function loss. 
However, non-albuminuric diabetic nephropathy is associ-
ated with a higher prevalence of CVD and may be more 
reflective of macroangiopathy than microangiopathy, which 
is the subject of this study [33]. In the present study, we 
analyzed renal disease based on albuminuria. This means 
that individuals with non-albuminuric diabetic nephropa-
thy are not taken into account in our analyses. Second, 
neuropathy data were only available for patients that were 
under surveillance in the hospitals. This reduced power for 
these analyses and generalizability to non-hospital patients. 
Also, height is a risk factor for neuropathy that we did not 
have available for correction in our models. Third, partici-
pation bias needs to be considered; however, we collected 
from both primary and secondary care, and in both of these 
populations, high rate of complications was found. There-
fore, a “healthy volunteer” bias seems unlikely. Finally, to 
investigate whether sex hormones played a role we repeated 
our analyses excluding women below the age of 51. This is 
a surrogate way of excluding premenopausal women and 
does not exclude residual effects of sex hormones on the 
outcome. Unfortunately we have no measures of sex hor-
mones available in our study population to investigate this 
in more detail. In conclusion, we found that men are at a 
higher prospective risk of several microvascular complica-
tions even after correcting for conventional risk factors. 
This underlines that men and women may not benefit to a 
similar extent from current treatment approaches to pre-
vent microvascular complications. Future studies should 
be directed at investigating the underlying mechanism of 
this association and to use this knowledge for improving 
personalized treatment strategies to prevent microvascular 
complication in type 2 diabetes.
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